Multistep carcinogenesis of breast cancer and tumour heterogeneity

Abstract Breast cancer emerges by a multistep process which can be broadly equated to transformation of normal cells via the steps of hyperplasia, premalignant change and in situ carcinoma. The elucidation of molecular interdependencies, which lead to development of primary breast cancer, its progression, and its formation of metastases is the main focus for new strategies targetted at prevention and treatment. Cytogenetic and molecular genetic analysis of breast cancer samples demonstrates that tumour development involves the accumulation of various genetic alterations including amplification of oncogenes and mutation or loss of tumour suppressor genes. Amplification of certain oncogenes with concomitant overexpression of the oncoprotein seems to be specific for certain histological types. Loss of normal tumour suppressor protein function can occur through sequential gene mutation events (somatic alteration) or through a single mutational event of a remaining normal copy, when a germline mutation is present. The second event is usually chromosome loss, mitotic recombination, or partial chromosome deletion. Chromosome loci 16q and 17p harbour tumour suppressor genes, which seem to be pathognomonic for the development or progression of a specific histological subtype. There are an overwhelming number of abnormalities that have been identified at the molecular level which fit the model of multistep carcinogenesis of breast cancer. When the functions of all of these genes are known and how they participate in malignant progression, we will have the tools for a more rational approach to diagnosis, prevention and treatment. This review deals only with the factors that are involved in the conversion of a normal breast cell into a malignant cell rather than those required for invasion and metastases. A key critical long-term step in the molecular analysis of breast cancer will be to link the specific molecular damage with the effects of environmental carcinogens.

[1]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[2]  L. Brinton,et al.  Breast cancer risk associated with proliferative breast disease and atypical hyperplasia , 1993, Cancer.

[3]  W. Willett,et al.  Breast cancer (3). , 1992, The New England journal of medicine.

[4]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[5]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[6]  J. Hendriks,et al.  Microcalcifications associated with ductal carcinoma in situ: mammographic-pathologic correlation. , 1994, Seminars in diagnostic pathology.

[7]  M. J. van de Vijver,et al.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.

[8]  M. Skolnick,et al.  A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. , 1995, JAMA.

[9]  M. Skolnick,et al.  BRCA1 mutations in primary breast and ovarian carcinomas. , 1994, Science.

[10]  F. Collin,et al.  Benign breast disease: absence of genetic alterations at several loci implicated in breast cancer malignancy. , 1995, Cancer research.

[11]  D. Toft,et al.  Steroid receptors and their associated proteins. , 1993, Molecular endocrinology.

[12]  G. Peters.  The D-type cyclins and their role in tumorigenesis , 1994, Journal of Cell Science.

[13]  R. Lidereau,et al.  Identification of three regions on chromosome 17q in primary human breast carcinomas which are frequently deleted. , 1993, Cancer research.

[14]  W. McGuire,et al.  Prognostic factors and treatment decisions in axillary-node-negative breast cancer. , 1992, The New England journal of medicine.

[15]  J. Bartek,et al.  Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. , 1994, Cancer research.

[16]  D. Beach,et al.  Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. , 1993, Genes & development.

[17]  S. Seal,et al.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. , 1994, Science.

[18]  M. Beckmann,et al.  Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer. , 1996, British Journal of Cancer.

[19]  D. Louis,et al.  Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas. , 1994, Cancer research.

[20]  D. Niederacher,et al.  Patterns of allelic loss on chromosome 17 in sporadic breast carcinomas detected by fluorescent‐labeled microsatellite analysis , 1997, Genes, chromosomes & cancer.

[21]  P. Ravdin,et al.  Prognostic factors in early breast carcinoma , 1994, Cancer.

[22]  D. Carney,et al.  Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. , 1995, British Journal of Cancer.

[23]  D. Taverna,et al.  ErbB‐2 expression in estrogen‐receptor‐positive breast‐tumor cells is regulated by growth‐modulatory reagents , 1994, International journal of cancer.

[24]  M. Bortoli,et al.  Hormonal regulation of c-erbB-2 oncogene expression in breast cancer cells , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[25]  J. A. Hamilton,et al.  Expression and amplification of cyclin genes in human breast cancer. , 1993, Oncogene.

[26]  G. Martin,et al.  Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. , 1994, Science.

[27]  M. D. De Latour,et al.  Detection of allelic losses on 17q12-q21 chromosomal region in benign lesions and malignant tumors occurring in a familial context. , 1994, Oncogene.

[28]  K. Kerlikowske,et al.  Incidence of and treatment for ductal carcinoma in situ of the breast. , 1996, JAMA.

[29]  M. Beckmann,et al.  Expression analyses of epidermal growth factor receptor and HER-2/neu: no advantage of prediction of recurrence or survival in breast cancer patients. , 1996, Oncology.

[30]  P. Devilee,et al.  Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13. , 1995, British Journal of Cancer.

[31]  C. Osborne,et al.  HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  B. Gusterson.  Prognostic variables and future predictors of behaviour and response. , 1996, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[33]  J. Cleveland,et al.  c-Myc and apoptosis. , 1995, Biochimica et biophysica acta.

[34]  H. Nguyen,et al.  Hormone-dependent regulation of BRCA1 in human breast cancer cells. , 1995, Cancer research.

[35]  W. Dupont,et al.  Invasive breast cancer risk in women with sclerosing adenosis , 1989, Cancer.

[36]  Barbara L. Smith,et al.  Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. , 1996, The New England journal of medicine.

[37]  C. Mathew,et al.  Loss of heterozygosity of the oestrogen receptor gene in breast cancer. , 1995, British Journal of Cancer.

[38]  J. Barrett,et al.  Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms. , 1992, Cancer research.

[39]  E. Mallon,et al.  Interphase cytogenetic analysis of erbB2 and topollα co‐amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ , 1995, International journal of cancer.

[40]  N. Risch,et al.  An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. , 1993, The New England journal of medicine.

[41]  D. Demetrick,et al.  Chromosomal mapping of human CDK2, CDK4, and CDK5 cell cycle kinase genes. , 1994, Cytogenetics and cell genetics.

[42]  Y. Nakamura,et al.  Allele loss on chromosome 16q24.2-qter occurs frequently in breast cancers irrespectively of differences in phenotype and extent of spread. , 1994, Cancer research.

[43]  J. Foekens,et al.  Prognostic factors in human primary breast cancer: Comparison of c-myc and HER2/neu amplification , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[44]  E. Schuuring,et al.  Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. , 1992, Oncogene.

[45]  P. Watson,et al.  Relationship of c-myc amplification to progression of breast cancer from in situ to invasive tumor and lymph node metastasis. , 1993, Journal of the National Cancer Institute.

[46]  W D Dupont,et al.  Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.

[47]  G. Greene,et al.  Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival , 1990, Cancer.

[48]  N. Phillips,et al.  Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. , 1995, Cancer research.

[49]  D M Barnes,et al.  Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? , 1992, European journal of cancer.

[50]  A. Tanigami,et al.  Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. , 1990, Cancer research.

[51]  G. Merlo,et al.  Loss of heterozygosity on chromosome 17p13 in breast carcinomas identifies tumors with high proliferation index. , 1992, The American journal of pathology.

[52]  J. Dudley,et al.  Analysis of the int-1, int-2, c-myc, and neu oncogenes in human breast carcinomas. , 1990, Cancer research.

[53]  A. Sahin,et al.  Comparative allelotype of in situ and invasive human breast cancer: high frequency of microsatellite instability in lobular breast carcinomas. , 1995, Cancer research.

[54]  W. Cavenee,et al.  Loss of heterozygosity in human ductal breast tumors indicates a recessive mutation on chromosome 13. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[55]  J. Herman,et al.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. , 1995, Cancer research.

[56]  M. King,et al.  BRCA1 is secreted and exhibits properties of a granin , 1996, Nature Genetics.

[57]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[58]  H. Preisler,et al.  c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. , 1992, Cancer research.

[59]  M. Pike,et al.  The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. , 1988, European journal of cancer & clinical oncology.

[60]  M. Beckmann,et al.  ERBB2 gene amplification detected by fluorescent differential polymerase chain reaction in paraffin‐embedded breast carcinoma tissues , 1995, International journal of cancer.

[61]  S. Baylin,et al.  p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3 , 1995, Nature Genetics.

[62]  D. Birnbaum,et al.  Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. , 1996, Cancer research.

[63]  G. Hampton,et al.  Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. , 1994, Cancer research.

[64]  L. Liotta,et al.  Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast cancer. , 1995, Cancer research.

[65]  D. F. Easton,et al.  The genetics of breast and ovarian cancer. , 1995, British Journal of Cancer.

[66]  Junzhe Xu,et al.  The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues , 1995, Nature Genetics.

[67]  W. McGuire,et al.  Estrogen receptor mutations in breast cancer , 1993, Journal of cellular biochemistry.

[68]  C. M. Steel,et al.  Evidence implicating at least two genes on chromosome 17p in breast carcinogenesis , 1990, The Lancet.

[69]  B. Katzenellenbogen,et al.  Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: antiestrogen selectivity and promoter dependence. , 1994, Molecular endocrinology.

[70]  L. Garfinkel,et al.  Changing trends: An overview of breast cancer incidence and mortality , 1994, Cancer.

[71]  L. Sobin,et al.  Histological Typing of Breast Tumors 1 , 1982 .

[72]  D. Ledbetter,et al.  Detailed analysis of loss of heterozygosity on chromosome band 17p13 in breast carcinoma on the basis of a high‐resolution physical map with 29 markers , 1994, Genes, chromosomes & cancer.

[73]  Earlybreastcancertrialistscol,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.

[74]  P. Devilee,et al.  Somatic genetic changes in human breast cancer. , 1994, Biochimica et biophysica acta.

[75]  W. McGuire,et al.  Prognostic factors and therapeutic decisions in axillary node-negative breast cancer. , 1992, Annual review of medicine.

[76]  Rochelle L. Garcia,et al.  C‐ERBB‐2 oncogens protein in In situ and invasive lobular breast neoplasia , 1991 .

[77]  S. Ashley,et al.  Immunohistochemical distribution of c‐erbB‐2 in in situ breast carcinoma—a detailed morphological analysis , 1990, The Journal of pathology.

[78]  B. Gusterson,et al.  Prenatal factors may influence predisposition to breast cancer. , 1994, European journal of cancer.

[79]  B. Ljung,et al.  The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. , 1992, Oncogene.

[80]  R. Tarone,et al.  Involution and the etiology of breast cancer , 1994, Cancer.

[81]  T. Katagiri,et al.  Association of genetic alterations on chromosome 17 and loss of hormone receptors in breast cancer. , 1995, British Journal of Cancer.

[82]  C. Osborne,et al.  Aberrant Subcellular Localization of BRCA1 in Breast Cancer , 1995, Science.

[83]  J. Russo,et al.  Development pattern of human breast and susceptibility to carcinogenesis. , 1993, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[84]  M. Stratton,et al.  Loss of heterozygosity in ductal carcinoma in situ of the breast , 1995, The Journal of pathology.

[85]  B. Gusterson,et al.  c-erbB-2 expression in benign and malignant breast disease. , 1988, British Journal of Cancer.

[86]  M. Greene,et al.  Genetics of breast cancer. , 1997, Mayo Clinic proceedings.

[87]  D. W. Thompson.  Genetic epidemiology of breast cancer , 1994, Cancer.

[88]  M. Stratton,et al.  Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal, neoplastic proliferations. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[89]  An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. , 1993 .

[90]  C. Larsson,et al.  Deletions on chromosome 16 in primary familial breast carcinomas are associated with development of distant metastases. , 1993, Cancer research.

[91]  Daniel Metzger,et al.  Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase , 1995, Science.

[92]  G. Peters,et al.  Gene amplification on chromosome band 11q13 and oestrogen receptor status in breast cancer. , 1990, European journal of cancer.

[93]  B. Ljung,et al.  Heterogeneity for allelic loss in human breast cancer. , 1992, Journal of the National Cancer Institute.

[94]  S. Hirohashi,et al.  correlation between histologic grade of malignancy and copy number of c‐erbb‐2 gene in breast carcinoma. A retrospective analysis of 176 cases , 1990, Cancer.

[95]  S J London,et al.  A prospective study of benign breast disease and the risk of breast cancer. , 1992, JAMA.

[96]  J. Biggart,et al.  c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma. , 1992, Journal of clinical pathology.

[97]  Kathleen R. Cho,et al.  Genetic alterations in the adenoma–carcinoma sequence , 1992, Cancer.

[98]  A. Lupulescu.  Estrogen use and cancer risk: a review. , 2009, Experimental and clinical endocrinology.

[99]  J. D. Thompson,et al.  BRCA1 mutations in a population-based sample of young women with breast cancer. , 1996, The New England journal of medicine.

[100]  E. Imyanitov,et al.  Loss of heterozygosity at chromosome 17p is associated with HER‐2 amplification and lack of nodal involvement in breast cancer , 1993, International journal of cancer.

[101]  S. Baylin,et al.  Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. , 1995, Cancer research.

[102]  M. Merino,et al.  Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions , 1995, Nature Medicine.

[103]  David L. Page,et al.  Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression , 1995, Nature Genetics.

[104]  L. Hartwell,et al.  Cell cycle control and cancer. , 1994, Science.

[105]  A. Forrest,et al.  ALLELE LOSS ON SHORT ARM OF CHROMOSOME 17 IN BREAST CANCERS , 1988, The Lancet.

[106]  H. J. Evans,et al.  p53 allele losses, mutations and expression in breast cancer and their relationship to clinico‐pathological parameters , 1992, International journal of cancer.

[107]  J. Foekens,et al.  c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. , 1992, Cancer research.

[108]  J. Andersen.  Lobular carcinoma in Situ of the breast: An approach to rational treatment , 1977, Cancer.

[109]  H. Busch.  The Final Common Pathway of Cancer: Presidential Address , 1990 .

[110]  G. Greene,et al.  An immunohistochemical evaluation of progesterone receptor in frozen sections, paraffin sections, and cytologic imprints of breast carcinomas , 1991, Cancer.

[111]  M. Lovett,et al.  A single ataxia telangiectasia gene with a product similar to PI-3 kinase. , 1995, Science.

[112]  B. Katzenellenbogen,et al.  Antiestrogens: Mechanisms and actions in target cells , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[113]  J. Nesland,et al.  Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas , 1992, Genes, chromosomes & cancer.

[114]  D. Torgerson.  Risk factors for breast cancer , 1994, BMJ.

[115]  M. Stratton,et al.  Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. , 1995, Journal of clinical pathology.

[116]  S. Shapiro,et al.  Risk factors for breast cancer. , 1983, American journal of epidemiology.

[117]  W. Dupont,et al.  Relative risk of breast cancer varies with time since diagnosis of atypical hyperplasia. , 1989, Human pathology.

[118]  L. Mettler,et al.  Amplification of c-myc but not of c-erbB-2 is associated with high proliferative capacity in breast cancer. , 1993, Cancer research.

[119]  J. Rommens,et al.  The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds , 1996, Nature Genetics.

[120]  David L. Page,et al.  Atypical hyperplastic lesions of the female breast. A long‐term follow‐up study , 1985, Cancer.

[121]  C. Bodian,et al.  Breast Carcinoma: Risk and Detection , 1981 .

[122]  J. Landers,et al.  Steroid hormone regulation of nuclear proto-oncogenes. , 1993, Endocrine reviews.

[123]  H. J. Evans,et al.  p53 mutations in breast cancer. , 1992, Cancer research.

[124]  M. Parker,et al.  Characterization of ligand-dependent phosphorylation of the estrogen receptor. , 1994, Molecular endocrinology.

[125]  M. Vijver,et al.  E‐cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. , 1995, The EMBO journal.

[126]  R. Zeillinger,et al.  Patterns of allele losses suggest the existence of five distinct regions of loh on chromosome 17 in breast cancer , 1994, International journal of cancer.

[127]  S. Syrjänen,et al.  Tumourigenesis associated with the p53 tumour suppressor gene. , 1993, British Journal of Cancer.

[128]  D. Taverna,et al.  Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. , 1990, Oncogene.

[129]  K. Chew,et al.  Loss of heterozygosity and p53 gene mutations in breast cancer. , 1994, Cancer research.

[130]  W. Lee,et al.  Inactivation of the retinoblastoma susceptibility gene in human breast cancers. , 1988, Science.